Therapeutic advances in COVID-19
Author:
Publisher
Springer Science and Business Media LLC
Subject
Nephrology
Link
https://www.nature.com/articles/s41581-022-00642-4.pdf
Reference165 articles.
1. Karim, S. S. A. & Karim, Q. A. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet 398, 2126–2128 (2021).
2. Flythe, J. E. et al. Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States. Am. J. Kidney Dis. 77, 190–203.e1 (2021).
3. Massie, A. B. et al. Quantifying excess deaths among solid organ transplant recipients in the COVID-19 era. Am. J. Transplant. 22, 2077–2082 (2022).
4. Chan, L. et al. AKI in hospitalized patients with COVID-19. J. Am. Soc. Nephrol. 32, 151–160 (2021).
5. Gupta, S. et al. AKI treated with renal replacement therapy in critically ill patients with COVID-19. J. Am. Soc. Nephrol. 32, 161–176 (2021).
Cited by 59 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Peptidomimetics as potent dual SARS-CoV-2 cathepsin-L and main protease inhibitors: In silico design, synthesis and pharmacological characterization;European Journal of Medicinal Chemistry;2024-02
2. Soluble Angiotensin-Converting Enzyme 2 Protein Improves Survival and Lowers Viral Titers in Lethal Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Type 2 Infection with the Delta Variant;Cells;2024-01-23
3. Habitual salt preference worsens blood pressure in hospitalized hypertensive patients with omicron infection under epidemic-related stress;BMC Public Health;2024-01-09
4. Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection;European Journal of Medicinal Chemistry;2024-01
5. Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters;Antiviral Research;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3